Exploring Pathology Related to Slowly Expanding Lesions Using Advanced Imaging
Key facts
- Where
- Turku, FinlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06460077, who can take part
Where in Finland
- Turku PET CentreTurku, FinlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Turku University Hospital
- Trial code
- NCT06460077
- Record updated
- 16 April 2025
- Original description
This is an open, follow-up study to compare the performance of three critical imaging methods to detect chronic active lesions in Multiple Sclerosis (MS) in vivo.Read full original descriptionShow less
This is an open, follow-up study to compare the performance of three critical imaging methods to detect chronic active lesions in Multiple Sclerosis (MS) in vivo.
Inclusion: Signing the informed consent form; MS diagnosis in accordance with McDonald 2017 criteria; Available longitudinal brain MR images (minimum 1 year); Simultaneous QSM MRI sequence and TSPO-PET; Lesions with iron rim/s.
Exclusion: Corticosteroid treatment within 4 weeks of imaging; Exposure to experimental radiation in the past 12 months such that radiodosimetry limits would be exceeded by participating in this study; Intolerance to previous PET scans; i.e. previous hypersensitivity reactions to any PET ligand or imaging agent or failure to participate in and comply with previous PET scans; Patients with other neurodegenerative disease than MS; Patients with other autoimmune disease than MS; Patients with other significant or malignant underlying disease of any other organ system; Patients with claustrophobia, or a history of moderate to severe anxiety disorder or panic attacks (which could potentially lead to preterm termination of the imaging); Patients that are pregnant or breast-feeding; Patients with significant abnormal findings other than MS in the screening MRI; Contraindication to PET scan investigations.